2.72% -0.0102

23andMe Holding Co (ME)

23andMe Holding Co Borsa (ME) Ultime notizie

23andMe Holding Co (ME)

23andMe Holding Co Borsa (ME) Ultime notizie

23andMe Launches New Genetic Report on Bipolar Disorder - GlobeNewswire

23andMe Launches New Genetic Report on Bipolar Disorder

23andMe announces preliminary Phase 2 safety results for 23ME-00610 at ASCO - TipRanks.com - TipRanks

Why 23andMe Stock Tumbled 10% on Tuesday

23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black ... - GlobeNewswire

23andMe reports positive phase 2 data for cancer drug By Investing.com - Investing.com Nigeria

23andMe reports positive phase 2 data for cancer drug By Investing.com - Investing.com Canada

Citi maintains neutral stance on 23andMe with $0.63 target By Investing.com - Investing.com Canada

Citi maintains neutral stance on 23andMe with $0.63 target By Investing.com - Investing.com Australia

Citi maintains neutral stance on 23andMe with $0.63 target By Investing.com - Investing.com

Citi maintains neutral stance on 23andMe with $0.63 target By Investing.com - Investing.com UK

Citi Reiterates Neutral Rating on 23andMe Holding (ME) - StreetInsider.com

Citi Reiterates Neutral Rating on 23andMe Holding (ME) - StreetInsider.com

23andMe reports positive phase 2 data for cancer drug By Investing.com - Investing.com

23andMe Reveals Promising Data for New Antibody at ASCO - TipRanks.com - TipRanks

23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting ... - GlobeNewswire

23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting

Swiss National Bank Decreases Position in 23andMe Holding Co. (NASDAQ:ME) - Defense World

Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history - GlobeNewswire

Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history - GlobeNewswire

Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history - Yahoo Canada Finance

Citi raises 23andMe target to $0.63, keeps 'neutral' stance - Investing.com India

Citi raises 23andMe target to $0.63, keeps 'neutral' stance By Investing.com - Investing.com Australia

Citi raises 23andMe target to $0.63, keeps 'neutral' stance By Investing.com - Investing.com

Citi raises 23andMe target to $0.63, keeps 'neutral' stance By Investing.com - Investing.com Canada

Citi raises 23andMe target to $0.63, keeps 'neutral' stance By Investing.com - Investing.com UK

23andMe's business is basically worthless. Its CEO now wants to buy it. - Yahoo News Canada

Fact Check: About That Claim 23andMe Sold Genetic Data to Chinese Government - Yahoo News UK

23andMe Holding Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance UK

23andMe (NASDAQ:ME) Announces Quarterly Earnings Results - Defense World

TD Cowen bullish on 23andMe shares on Q4 revenue beat, strategic review By Investing.com - Investing.com Australia

TD Cowen bullish on 23andMe shares on Q4 revenue beat, strategic review By Investing.com - Investing.com

Earnings call: 23andMe reviews strategic options amid revenue decline - Investing.com South Africa

Earnings call: 23andMe reviews strategic options amid revenue decline - Investing.com Canada

23andMe Holding Co. (NASDAQ:ME) Q4 2024 Earnings Call Transcript - Insider Monkey

Earnings call: 23andMe reviews strategic options amid revenue decline - Investing.com India

23andMe Holding Co. (NASDAQ:ME) Q4 2024 Earnings Call Transcript - Insider Monkey

Earnings call: 23andMe reviews strategic options amid revenue decline By Investing.com - Investing.com

Earnings call: 23andMe reviews strategic options amid revenue decline By Investing.com - Investing.com UK

Q4 2024 23andMe Holding Co. Earnings Call Transcript - GuruFocus.com

Earnings call: 23andMe reviews strategic options amid revenue decline By Investing.com - Investing.com

23andMe Gains as Revenue Beats Despite Flagging DNA Sales - Bloomberg

23andMe stock soars nearly 10% after delivering top-line beat in Q4 - Investing.com South Africa

23andMe, citing strategic alternatives review, not providing fiscal 2025 guidance - Seeking Alpha

23andMe stock soars nearly 10% after delivering top-line beat in Q4 By Investing.com - Investing.com Canada

23andMe stock soars nearly 10% after delivering top-line beat in Q4 - Investing.com Australia

23andMe stock soars nearly 10% after delivering top-line beat in Q4 - Investing.com India

23andMe stock soars nearly 10% after delivering top-line beat in Q4 By Investing.com - Investing.com

23andMe stock soars nearly 10% after delivering top-line beat in Q4 By Investing.com - Investing.com UK

23andMe Holding Co. (ME) Misses Q4 EPS by 28c - StreetInsider.com

Simile a ME